These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37762037)

  • 1.
    Coan M; Toso M; Cesaratto L; Rigo I; Borgna S; Dalla Pietà A; Zandonà L; Iuri L; Zucchetto A; Piazza C; Baldassarre G; Spizzo R; Nicoloso MS
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762037
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LINC01605 promotes aerobic glycolysis through lactate dehydrogenase A in triple-negative breast cancer.
    Wang W; He X; Wang Y; Liu H; Zhang F; Wu Z; Mo S; Chen D
    Cancer Sci; 2022 Aug; 113(8):2484-2495. PubMed ID: 35411612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer.
    Qin Z; Wang Y; Tang J; Zhang L; Li R; Xue J; Han P; Wang W; Qin C; Xing Q; Yang J; Zhang W
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30054424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
    Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
    Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Mutant p53 in the Non-Coding RNA World.
    Di Agostino S
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32204575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-coding RNAs, guardians of the p53 galaxy.
    Chen S; Thorne RF; Zhang XD; Wu M; Liu L
    Semin Cancer Biol; 2021 Oct; 75():72-83. PubMed ID: 32927018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINC01605 regulates proliferation, migration and invasion of colorectal cancer cells via targeting miR-3960/SOX11.
    Hu SS; Fu L; Han SY; Li XL; Zhang LD
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1322-1329. PubMed ID: 33629302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
    Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
    J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
    Song H; Hollstein M; Xu Y
    Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant TP53 posttranslational modifications: challenges and opportunities.
    Nguyen TA; Menendez D; Resnick MA; Anderson CW
    Hum Mutat; 2014 Jun; 35(6):738-55. PubMed ID: 24395704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
    Abdel-Rahman WM; Al-Khayyal NA; Nair VA; Aravind SR; Saber-Ayad M
    World J Gastroenterol; 2017 May; 23(19):3440-3448. PubMed ID: 28596680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone modifications affect differential regulation of TGFβ- induced NADPH oxidase 4 (NOX4) by wild-type and mutant p53.
    Boudreau HE; Ma WF; Korzeniowska A; Park JJ; Bhagwat MA; Leto TL
    Oncotarget; 2017 Jul; 8(27):44379-44397. PubMed ID: 28574838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
    Barta JA; Pauley K; Kossenkov AV; McMahon SB
    Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
    Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
    Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant p53 mediates survival of breast cancer cells.
    Lim LY; Vidnovic N; Ellisen LW; Leong CO
    Br J Cancer; 2009 Nov; 101(9):1606-12. PubMed ID: 19773755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA NEAT1 is a transcriptional target of p53 and modulates p53-induced transactivation and tumor-suppressor function.
    Idogawa M; Ohashi T; Sasaki Y; Nakase H; Tokino T
    Int J Cancer; 2017 Jun; 140(12):2785-2791. PubMed ID: 28295289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.